Neurotrope Inc. shares plummeted 33.6% in premarket trade Monday after the company released mid-stage clinical trial results for an Alzheimer’s disease drug that were criticized by investors. Though Neurotrope sought to portray Monday’s phase 2 results as positive, claiming they showed a benefit for patients with moderate-to-severe Alzehimer’s disease, investors questioned the company’s presentation of the results, since one of the patient groups treated with Neurotrope’s Bryostatin-1 did not meet the primary endpoint and the company focused on the results for a lower dose of the drug. Both a 20 µg dose and a 40 µg dose were tested in the clinical trial, but Neurotrope only reported results for the 20 µg group in its release early Monday. Company shares have surged 68.3% to $18.81 over the last three months, compared with a 4.6% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News